Otc - Active Ingredient
Guafenesin 200 mg
The following Structured Product Label (SPL) was submitted to the FDA by Rnv Llc for the product Revasol Tussin (NDC 84379-313). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding otc - active ingredient, otc - purpose, indications & usage, warnings, otc - pregnancy or breast feeding, otc - keep out of reach of children, dosage & administration, inactive ingredient, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
Guafenesin 200 mg
Expectorant
Uses
helps loosen phlegm (mucus) and thin bronchial
secretions to rid the bronchial passageways of bothersome mucus.
Warning
Ask a doctor before use if you have • a persistent or chronic
cough such as occurs wiht smoking, asthma, chronic bronchitis, or
emphysema or where cough is accompanied by excessive phlegm
(mucus)
Stop use and ask a doctor if • cough persists for more than 1
week, tends to recur, or is accompanied by a fever, rash, or
persistent headache. A persistent cough may be a sign of a serious
condition.
If pregnant or breast-feeding, ask a health professional before
use
Keep out of the reach of children. In case of accidental overdose,
get medical help or contact a Poison Control Center right away.
Directions
Directions:
do not exceed more than 6 doses in any 24-hour period
shake well before use
measure only with dosing cup provided
keep dosing cup with product
mL=mililiter TSP=teaspoonful
this adult product is not intended for use in children
| Age | Dose |
| adults and children 12 years of age and over | 10 mL (2 teaspoonful) every 4 hours |
| children under 12 years of age | do not use |
Inactive ingredients citric acid, FD&C #40, flavors, glycerin,
menthol, propylene glycol, sodium benzoate, sucralose, water.
Questions or comments: 305-821-4002
Monday - Friday (9 AM - 5 PM EST)
* Please review the disclaimer below.